Stock TARO TARO PHARMACEUTICAL INDUSTRIES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Taro Pharmaceutical Industries Ltd.

Equities

TARO

IL0010827181

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
42.4 USD -0.19% Intraday chart for Taro Pharmaceutical Industries Ltd. +0.36% +1.48%
Jan. 25 Taro Pharmaceutical Industries Fiscal Q3 Net Income, Net Sales Rise; Shares Climb After Hours MT
Jan. 25 Taro Pharmaceutical Industries Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024
Capitalization 1 4,218 2,341 2,822 1,626 914.1 1,594
Enterprise Value (EV) 1 4,218 2,341 2,822 1,626 914.1 1,594
P/E ratio 15 x 9.64 x -7.29 x 27.9 x 35.8 x 38.5 x
Yield - - - - - -
Capitalization / Revenue 6.3 x 3.63 x 5.14 x 2.9 x 1.6 x 2.58 x
EV / Revenue 6.3 x 3.63 x 5.14 x 2.9 x 1.6 x 2.58 x
EV / EBITDA 13,556,545 x - - - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 2.21 x - - - - -
Nbr of stocks (in thousands) 39,019 38,258 38,258 37,585 37,585 37,585
Reference price 2 108.1 61.20 73.75 43.26 24.32 42.40
Announcement Date 5/22/19 5/19/20 5/19/21 5/27/22 5/24/23 -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024
Net sales 1 669.9 644.8 549 561.3 573 618.1
EBITDA 311.1 - - - - -
EBIT 1 292.5 246.5 145.1 124.9 17.71 -1.241
Operating Margin 43.67% 38.24% 26.44% 22.25% 3.09% -0.2%
Earnings before Tax (EBT) 1 356.9 298 -391.1 77.86 38.21 53.54
Net income 1 281.8 244.2 -386.7 58.27 25.44 41.41
Net margin 42.06% 37.88% -70.43% 10.38% 4.44% 6.7%
EPS 2 7.230 6.350 -10.12 1.550 0.6800 1.100
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/22/19 5/19/20 5/19/21 5/27/22 5/24/23 -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 140.1 148.3 147.1 132 139 143.3 156.7 130.5 139.2 146.6 158.9 161.1 154.9 156.1
EBITDA - - - - - - - - - - - - - -
EBIT 1 36.31 38.11 40.8 24.45 36.97 21.28 13.98 -6.815 1.279 9.274 -1.7 -1.098 1.032 0.91
Operating Margin 25.91% 25.69% 27.73% 18.52% 26.6% 14.85% 8.92% -5.22% 0.92% 6.33% -1.07% -0.68% 0.67% 0.58%
Earnings before Tax (EBT) 1 39.14 -37.76 -16.08 29.42 39.5 25.02 16.05 -4.913 9.172 17.9 5.44 8.902 15.03 15.41
Net income 1 32.92 -29.79 -18.77 23.32 26.31 27.4 14.08 -2.813 7.265 6.913 10.03 6.676 11.27 11.56
Net margin 23.49% -20.08% -12.76% 17.67% 18.93% 19.13% 8.99% -2.16% 5.22% 4.72% 6.31% 4.14% 7.28% 7.41%
EPS 2 0.8600 -0.7800 -0.5000 0.6200 0.7000 0.7300 0.3700 -0.0700 0.1900 0.1800 0.2700 0.1800 0.3000 0.3100
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 1/27/21 5/19/21 7/27/21 10/28/21 1/27/22 5/27/22 7/27/22 10/27/22 1/24/23 5/24/23 7/27/23 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 48.90 - - - - -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 5/22/19 5/19/20 5/19/21 5/27/22 5/24/23 -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
42.4 USD
Average target price
43 USD
Spread / Average Target
+1.42%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TARO PHARMACEUTICAL INDUSTRIES LTD. Stock Taro Pharmaceutical Industries Ltd.
+1.48% 1.59B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TARO Stock
  4. Financials Taro Pharmaceutical Industries Ltd.